Improved Drinking Behaviour Improves Quality of Life: A Follow-Up in Alcohol-Dependent Subjects 7 Years After Treatment
Improved Drinking Behaviour Improves Quality of Life: A Follow-Up in Alcohol-Dependent Subjects 7 Years After Treatment
复制标题
DOI：
10.1093/alcalc/agt038
复制
发表时间：
2013-09-01
影响因子：
2.8
通讯作者：
Mann, Karl
中科院分区：
文献类型：
--
作者：
Frischknecht, Ulrich;Sabo, Thomas;Mann, Karl
目的：本研究将酒精依赖患者治疗7年后的生活质量与饮酒状况联系起来，作为试验的常规终点。潜在的缓和因素，如患者的吸烟状况、额外的医疗保健使用和应激性生活事件被考虑在内。方法：127例酒依赖患者在接受酒精中毒治疗7年后，填写了《慕尼黑生活质量量表》(MLDL)，这是一份通用的生活质量问卷，并在电话访谈中进行了复查。评估患者在前一年的饮酒和吸烟行为，以及在整个随访期内是否经历过紧张的生活事件，以及额外的医疗保健使用情况。结果：报告戒酒或饮酒改善的患者的生活质量评分显著高于饮酒未改善的患者。吸烟状况对生活质量无显著影响。在随访期内使用额外医疗保健的患者报告生活质量较低。对于那些经历过紧张生活事件的人来说也是如此。结论：即使考虑到其他因素，如额外的医疗保健使用和应激生活事件，7年随访后饮酒情况的改善也与生活质量的改善有关。我们得出结论，在治疗试验中，QOL可以作为一个额外的终点。
Aim: The present study relates alcohol-dependent patients' Quality of Life (QoL) 7 years after treatment to drinking status as the conventional endpoint of trials. Potential moderating factors such as patients' smoking status, additional healthcare usage and stressful life events were accounted for. Methods: Seven years after being treated for alcoholism, n = 127 alcohol-dependent patients filled out the Munich List of Quality of Life Dimensions (MLDL), a generic QoL questionnaire and were re-examined in telephone interviews. Patients' drinking and smoking behaviours during the previous year and additional healthcare usage and whether or not they had experienced stressful life events during the whole follow-up period were assessed. Results: Patients reporting abstinence or improved drinking showed significantly higher QoL ratings than patients whose drinking had not improved. Smoking status had no significant effect on QoL. Patients who used additional healthcare during the follow-up period reported lower QoL. The same was true of those who had experienced stressful life events. Conclusions: Improved drinking after a 7-year follow-up is associated with improved QoL even when considering other factors such as additional healthcare use and stressful life events. We conclude that QoL can be an additional endpoint in treatment trials.